Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In this study, we have assessed the activation of the cannabinoid CB2 receptor (CB2-R) in a model of mouse myocardial ischemia/reperfusion (I/R). The results show that treatment of animals with WIN55212-2, a CB1/CB2-R agonist, given 30 min before induction of I/R, significantly reduced the extent of infarct size (IS) in the area at risk, as measured 2.5 h later, with almost a 51% inhibition observed at the dose tested of 3.5 mg/kg intraperitoneally (i.p.). The protective effect of WIN55212-2 was almost abolished by the selective CB2-R antagonist AM630 (1 mg/kg i.p.) and not affected by the selective CB1-R antagonist AM251 (3 mg/kg i.p.). The CB2-R antagonist administered alone produced a slight but significant (P<0.05) increase in IS compared with vehicle alone. The protection afforded by WIN55212-2 was paralleled by lower values of myeloperoxidase activity and interleukin-1β and of the CXC chemokine ligand 8 into the injured tissue. In conclusion, we demonstrate for the first time that exogenous and endogenous CB2-R activation reduces the leukocyte-dependent myocardial damage associated with an I/R procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“These effects are mediated by the activation of specific G protein-coupled receptors [26, 27], characterized and cloned from mammalian tissues CB1 [28] and CB2 [29].”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
Clayton, N., Marshall, F. H., Bountra, C., & O'Shaughnessy, C. T. (2002) · Pain · doi:10.1016/s0304-3959(01)00454-7 · Cited by 247
Sacerdote, P., Massi, P., Panerai, A. E., & Parolaro, D. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00307-6 · Cited by 124 · cited 2×
“Two CB-Rs have been identified so far, and recent data suggest that the type 2 or CB2-R, is the main peripheral molecular target responsible for the inhibitory properties of the cannabinoids [10, 11] and more importantly, for the cardioprotection afforded by these compounds [12–15] in models of inflammation-based tiss…”
Background
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
The CB2 receptor and its role as a regulator of inflammation
Turcotte, C., Blanchet, M.-R., Laviolette, M., & Flamand, N. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2300-4 · Cited by 588
Remote ischaemic preconditioning: underlying mechanisms and clinical application
Hausenloy, D. J., & Yellon, D. M. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn114 · Cited by 557
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.130 · Cited by 439
Metadata
- Authors
- Di Filippo, C., Rossi, F., Rossi, S., & D’Amico, M.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-04
- Volume
- 75
- Issue
- 3
- Pages
- 453-459
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2125376647
- Cited by
- 128
- References
- 4
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.